Palivizumab

Palivizumab is a medication used to help protect high-risk infants and young children from serious respiratory infections caused by the respiratory syncytial virus (RSV). It is a monoclonal antibody, meaning it is a lab-made protein that helps the immune system fight off the virus. Given as an injection, Palivizumab doesn't cure RSV but can significantly reduce the chance of severe illness, hospitalization, or complications in vulnerable children, such as those born prematurely or with certain heart or lung conditions. It is typically administered monthly during RSV season.